Why Is GTBP Stock Rising Today? GT Biopharma Shares Gain After TriKE Platform Presentation

GT Biopharma (GTBP) shares rose 12.78% in pre-market trading Friday as the company hosted a live presentation on its TriKE platform and clinical progress.

The webinar, titled "The TriKE Platform, Clinical Progress, and the Case for NK Cell Immunotherapy," aired at 2:00 p.m. Eastern Time and featured Michael Breen, Executive Chairman and CEO, alongside Dr. Jeffrey Miller, Consulting Senior Medical Director. The speakers discussed clinical progress in blood cancers and solid tumors, insights from increasing dose levels, the platform's competitive positioning, and key milestones ahead. A replay of the webcast will be available on gtbiopharma.com following the event.

GT Biopharma is a clinical-stage immuno-oncology company building therapeutics around its proprietary TriKE platform. The technology uses a bispecific molecule design to activate natural killer cells to target tumor antigens. The second-generation TriKE molecules are 10 to 40 times more potent than the first generation, and all current development focuses on that platform. The lead clinical program, GTB-3650, targets CD33-positive leukemias, including AML and MDS. The IND application was cleared and enrollment started earlier this year.

The move is sizable for a presentation-driven event, so additional unconfirmed factors may be contributing to the price action. Pre-market liquidity is typically thinner than regular-session trading, so the full picture may not emerge until standard trading hours. Investors will want to watch for the webcast replay and look for details on any clinical timeline updates, new dose-level findings, or pipeline milestones referenced during the presentation.